CN103202824B - Application of pinitol to pharmacy and health care product - Google Patents
Application of pinitol to pharmacy and health care product Download PDFInfo
- Publication number
- CN103202824B CN103202824B CN201310055954.8A CN201310055954A CN103202824B CN 103202824 B CN103202824 B CN 103202824B CN 201310055954 A CN201310055954 A CN 201310055954A CN 103202824 B CN103202824 B CN 103202824B
- Authority
- CN
- China
- Prior art keywords
- pinitol
- application
- plasma
- health care
- insulin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention provides application of pinitol to pharmacy and health care product. Compared with the prior art, the invention has the beneficial effects that: novel medical application and health care application of a known compound is explored, and a new application field is developed; the product has rich source and simple preparation process, can be prepared into an oral preparation, an injection and tablet, and is convenient for use; the configured drug product or health care product has effects of increasing plasma levels of pinitol and D-chiro-inositol, and decreasing plasma insulin and glucose levels; and the configured drug product or health care product has effects of reducing the blood sugar value, insulin level, plasma lipid and plasma triglyceride.
Description
Technical field
The present invention relates to the purposes of loose alcohols material in pharmacy or health product.
Background technology
Pinitol is a kind of known compound, and its molecular formula is C
7h
14o
6, its molecular weight is 194.18, No. CAS is 10284-63-6, fusing point 178-185 DEG C.Prior art shows that pinitol is combined with creatine series products, creatine can be promoted to absorb thus speed the growth of muscle, is applied to body-building and increases flesh field.Due to cognitive to the shortage of this product, existing range of application is narrow.
Summary of the invention
The present invention proposes a kind of loose alcohols material and preparing the application that prevents and/or treats in insulin resistance disease medicament and/or health product, namely at pharmacy or the new opplication prepared in health product.
In fact, the present invention relates to loose alcohols material and prepare the application in the medicine or health product preventing and/or treating type Ⅱdiabetes mellitus and chronic complicating diseases thereof.
Relate to loose alcohols material and prepare the application in the medicine or health product preventing and/or treating obesity, hyperlipidemia, dyslipidemia arteriosclerosis, hypertension or cardiovascular disease.
Relate to loose alcohols material and prepare the application in the medicine or health product preventing and/or treating acquired immune deficiency syndrome (AIDS).
Relate to loose alcohols material and prevent and/or treat application in cancer or tuberculosis/cachectic medicine or health product in preparation.
Relate to loose alcohols material and prepare the application in the medicine or health product preventing and/or treating diabetes and chronic complicating diseases thereof.
Also relate to loose alcohols material and prevent and/or treat application in aging, the medicine of lupus and other autoimmune disease or health product in preparation.
Also relate to loose alcohols material and prevent and/or treat septicemia, burn, malnutrition and stress application in the medicine of class wound or health product in preparation.
Also relate to loose alcohols material and prepare the application in the medicine or health product preventing and/or treating endocrinopathy.
Also relate to loose alcohols material and prepare the application in the medicine or health product preventing and/or treating the hyperuricemia caused by sports or inertia.
Also relate to loose alcohols material and prepare the application in the medicine or health product preventing and/or treating many capsules ovum syndrome and complication.
Loose alcohols material of the present invention can be the compositions of pinitol, the derivant of pinitol, the metabolite of pinitol, the compositions of pinitol, the compositions of pinitol derivant or pinitol metabolite.
In use can single drug also can the medication simultaneously of multiple various medicaments type.For mammal per kilogram of body weight provides the pinitol of 1 to 10 mg/day and derivant thereof or metabolite, the mode of taking is oral.
According to the present invention, appropriate parenteral solutions is used to refer in sterile liquid carrier is as water or 1,3 butylene glycol containing pinitol or derivatives thereof or metabolite.
The derivant of described pinitol can be DCI.
The compositions of described pinitol can be the nutriment of good to eat clothes.The existence form of nutriment is various, such as mobility milk powder, block agent, tablet, capsule or other dosage form; Or liquid form, as oral in water base gold, intestinal or parenteral solutions, colloid solution or Emulsion.
The enteral composition of the compositions of pinitol of the present invention can comprise deionized water, pinitol, maltodextrin, sodium caseinate, solid starch syrup, medium chain triglyceride, canola oil, calcium caseinate, soybean protein, potassium citrate, magnesium chloride, sodium citrate, tricalcium phosphate, soybean lecithin, sodium ascorbate, choline chloride, potassium chloride, vitamin E, molybdenum yeast, selenium yeast, carrageenan, chromium yeast, biotin, nicotiamide, zinc sulfate, ferrous sulfate, calcium pantothenate, vitamin A, cobalamine, manganese sulfate, copper gluconate, vitamin K, thiamine, pyridoxine hydrochloride, vitamin D, riboflavin, folic acid, potassium iodide, defoamer, nature or artificial flavor and sweeting agent.Also following compositions be can add in enteral composition of the present invention, glucose, soybean oil, sunflower oil, canola oil, carnitine, taurine and other natural component comprised as beef, peach butter, Semen Pisi sativi, Semen phaseoli radiati and orange juice.
The compositions of pinitol of the present invention can comprise pinitol in Orally administered composition, moisture, maltodextrin, sugar, Semen Maydis oil, sodium caseinate, soybean protein isolate, calcium caseinate, potassium citrate thing, tricalcium phosphate, magnesium chloride, sodium citrate, lecithin, potassium chloride, choline chloride, ascorbic acid, potassium hydroxide, carrageenan, vitamin E, carrageenan, zinc sulfate, ferrous sulfate, nicotiamide, biotin, vitamin A, calcium pantothenate, copper gluconate, cobalamine, manganese sulfate, vitamin K, potassium, iodine and Nature and Man make flavouring agent.
Can comprise pinitol, defatted milk powder, sugar, cocoa powder, carrageenan, Tween-80, magnesium oxide, salt, vanillin, vitamin E in the oral powder composition of the compositions of pinitol of the present invention, ascorbic acid, Orthophosphoric acid Ferrum, zinc sulfate, vitamin A, nicotiamide, maltol, copper gluconate, calcium pantothenate, pyridoxine hydrochloride, thiamine, cobalamine, vitamin D3, folic acid, riboflavin, biotin and Nature and Man make flavouring agent.
This oral powder composition can mix with milk or water before taking, and then takes, and not only conveniently takes like this, also add nutrition.
Another kind of oral powder composition comprises maltodextrin, pinitol, citric acid, calcium hydroxide, salt, sweetener, ascorbic acid, potassium citrate, solid phase orange juice, vitamin E, Tween-60, zinc sulfate, ferrous sulfate, biotin, nicotiamide, copper gluconate, calcium pantothenate, cobalamine, vitamin D3, folic acid, pyridoxine hydrochloride, vitamin B2 and Nature and Man and makes flavouring agent and coloring agent.
Magnesium gluconate, dipotassium hydrogen phosphate, three water magnesium sulfates, manganese sulfate monohydrate and thiamine also can be comprised in the compositions of pinitol.
Further, take in powder composition the pinitol that also can comprise band dextrose or maltodextrin carrier, it can add in food or fruit juice.
The present invention can also with food chain for preferably to choose component, and it comprises pinitol, dried Fructus Vitis viniferae, pelletizing nut, Fructus Ananadis comosi, guar gum, protein mixture, glucose, caramel, Mel, high maltose syrup corn syrup, soybean oil, salt, magnesium oxide, vitamin and mineral element and Nature and Man makes flavouring agent and coloring agent.
Various compositionss in the present invention can also comprise other conventional ingredient as suspending agent or wetting agent, antiseptic, antioxidant, thickening agent etc.
Compared with prior art, the invention has the beneficial effects as follows:
(1) the present invention has excavated new medical application and health purpose to known compound, has opened up a new application;
(2) rule of origin of the present invention enriches, and preparation technology is simple, and can make peroral dosage form, injection type, tablet etc., easy to use;
(3) medicine that becomes of products configuration of the present invention or health product have and make the blood plasma level of pinitol and DCI increase, the effect that plasma insulin and blood sugar level decline
(4) medicine that becomes of products configuration of the present invention or health product have and reduce blood glucose value, reduce insulin level, reduce plasma adiponectin and reduce the effect of plasma triglyceride.
Accompanying drawing explanation
Fig. 1 is the change of injecting blood plasma inositol level, blood plasma pinitol level and DCI level after pinitol in pathological analysis embodiment 1;
Fig. 2 is the content of pinitol treatments period pinitol and inositol in pathological analysis embodiment 1 and the change of plasma insulin area.
Detailed description of the invention
Be clearly and completely described the technical scheme in the present invention below, obviously, described embodiment is only several embodiments wherein of the present invention, instead of whole embodiments.Based on the embodiment in the present invention, those of ordinary skill in the art, not making the every other embodiment obtained under creative work prerequisite, belong to the scope of protection of the invention.
Pathological analysis embodiment:
Embodiment 1
This example shows, suffer from 2 type non insulin dependent debates mellitus persons ingest the pinitol fraction extracted from Semen sojae atricolor time, the blood plasma level of pinitol and DCI can be caused to rise, and plasma insulin and blood sugar level decline.
Under two conditions five kinds of non-insulin-dependent diabetes mellitus bodies are studied week about.In continuous three days, the pinitol of the oral 4.15mg/kg/ of sick body days.Prepare the DCI also comprising 0.85mg/kg/ days other forms in liquid.By weight, the total content (comprising pinitol) of inositol is 22.5%.In 4th day morning, they do not take hypoglycemic medicine, and report to Clinical Research Center.Get basal blood sample, the oral pinitol when-60 typing when-90 and-60 typing, amount is the same with first three day.Material comprises the heat of less than 5 calories.Use 75g blood glucose to start blood carbohydrate tolerance test in zero moment, and in continuous three hours per half an hour get a blood sample.Patient takes in inose (5mg/kg/ days) or Semen sojae atricolor pinitol (total inositol content 5mg/kg/ days) at random.The impact of inose on blood glucose and insulin is not fixing, and it has prevents and treats function.Measure blood plasma inositol level by GC/MS Analysis, and measure insulin level by RIA.
Between control blood glucose tolerance test period, after injecting inose, the change of blood plasma inositol level is less.But as shown in Figure 1, after injecting pinitol, blood plasma pinitol becomes tens times to increase with DCI level.Oral pinitol is after three hours, and blood plasma pinitol reaches peak value 5.4uM, and plasma D-chiro-inositol level is always all lower than described peak value, and four hours after medication reach 1.7uM.Therefore, the outstanding role taking in Semen sojae atricolor pinitol is, improves blood plasma pinitol level.
As shown in table 1 and Fig. 2, pinitol treatments period observes, between blood glucose tolerance test period, plasma insulin reduces in a large number.Benchmark insulin and blood sugar level remain unchanged, but between blood glucose tolerance test period, insulin reduces in a large number, and it is from zero moment.Insulin area (uM/ml insulin × typing) reduces 25.2 ± 8.9%, p=0.046:
Table 1 five kinds of non-insulin-dependent diabetes mellitus body researchs
Between blood glucose tolerance test period, Blood glucose area (mg/dl × typing) reduces by 18.8 ± 9.1%, p=0.11 equally.
Embodiment 2
This example shows, the plasma triglyceride in plasma D-chiro-inositol and glycosuria sick body and high density lipoprotein contact closely.
In the process of the influence factor by cross sectional analysis plasma triglyceride and hdl level, have studied 19 kinds of insulin dependent diabetes mellitus (IDDM) bodies and 54 kinds of non-insulin-dependent diabetes mellitus bodies.As everyone knows, age, sex, constitutional index, companion's row pharmacotherapy, glycolated hemoglobin, blood plasma lipide are the covariant affecting plasma insulin and lipoprotein, and the present invention measures it.Measure plasma D-chiro-inositol, its measured value is used in multiple regression equation, prediction plasma triglyceride and HDL-C.The statistical association as following table 2 has been found by research:
Contacting of plasma triglyceride in table 2 plasma D-chiro-inositol and glycosuria sick body and high density lipoprotein
(R is multiple correlation coefficient)
Above-mentioned data show, rely in insulin-dependent at insulin-dependent and non-insulin, plasma D-chiro-inositol independently can indicate plasma triglyceride forcefully, and can indicate the high density lipoprotein in insulin dependent diabetes mellitus (IDDM) body forcefully.Insulin resistance component may be had in insulin dependent diabetes mellitus (IDDM) body.
Preparation embodiment:
Preparation D-pinitol capsule, its component is: D pinitol 600mg, vitamin D3 600iu, nicotinic acid chromium 250mcg.
Application Example:
The D-pinitol capsule prepared in application preparation embodiment carries out the clinical experiment for the treatment of type 2 diabetes mellitus, wherein treatment group 65 example, matched group 62 example:
(1) clinical manifestation and lab testing
(2) Therapeutic Method:
Two groups of patients all give identical Primary Care, i.e. less salt, low fat diet and diet control, influence of Aerobic Exercise.The next day monitoring fasting glucose and 2h-plasma glucose (referring to blood instrument).Take medicine, carry out in the following manner: (1) matched group: metformin hydrochloride tablet 0.5, Tid (after meal half h clothes), medication 30d is 1 course for the treatment of.(2) treatment group: on the basis of matched group, adds the D pinitol capsule with preparing in preparation embodiment, and instructions about how to take medicine are for often to take 1, and (every heavy 1000mg) every day 2 times, half h takes medicine after meal.
(3) observation of curative effect
A, criterion of therapeutical effect:
The control objectives [1] of reference Asian-Pacific area type 2 diabetes mellitus policy group formulation in 1999 is as criterion of therapeutical effect.
B, therapeutic outcome
(1) control objectives: after two groups of treatments, treatment group 65 example, effective 54 examples (wherein good 39 examples, general 15 examples), invalid 11 examples; Matched group 62 example, effective 33 examples (wherein good 19 examples, general 14 examples), invalid 29 examples, two groups are compared, χ 2=13.11, P<0.05.
(2) blood insulin changes of contents before and after treatment: before treatment group treatment, serum insulin content is (24.71 ± 3.1) μ u/mL, is (20.97 ± 2.17) μ u/mL after treatment; Being (24.57 ± 3.2) μ u/mL before treatment of control group, is (23.85 ± 2.57) μ u/mL after treatment, own control before and after treatment, equal P<0.05.
(4) clinical experiment conclusion
D-pinitol capsule has comparatively significantly curative effect to treatment type 2 diabetes mellitus, adds with after D-pinitol capsule for treating, the content of serum insulin by a relatively large margin lower.
The foregoing is only preferred embodiment of the present invention, not in order to limit the present invention, within the spirit and principles in the present invention all, any amendment done, equivalent replacement, improvement etc., all should be included within protection scope of the present invention.
Claims (2)
1. loose alcohols material is preparing the application in the medicine or health product preventing and/or treating type Ⅱdiabetes mellitus and chronic complicating diseases thereof.
2. the application of loose alcohols material according to claim 1 in pharmacy or health product, is characterized in that: described loose alcohols material is the compositions of pinitol, the derivant of pinitol, the metabolite of pinitol, the compositions of pinitol, the compositions of pinitol derivant or pinitol metabolite.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310055954.8A CN103202824B (en) | 2013-02-21 | 2013-02-21 | Application of pinitol to pharmacy and health care product |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310055954.8A CN103202824B (en) | 2013-02-21 | 2013-02-21 | Application of pinitol to pharmacy and health care product |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103202824A CN103202824A (en) | 2013-07-17 |
| CN103202824B true CN103202824B (en) | 2015-05-20 |
Family
ID=48750383
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310055954.8A Expired - Fee Related CN103202824B (en) | 2013-02-21 | 2013-02-21 | Application of pinitol to pharmacy and health care product |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103202824B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101908702B1 (en) * | 2015-11-09 | 2018-10-17 | 주식회사 디와이내츄럴 | Composition for Alleviating, Treating or Preventing Premenstrual Syndrome Comprising Pinitol, D-Chiro-inositol or Derivatives Thereof As Active Ingredient |
| CN106361768A (en) * | 2016-08-29 | 2017-02-01 | 宋延军 | Composition and preparation thereof for adjuvant therapy of hypertension and diabetes |
| CN107550923A (en) * | 2017-08-16 | 2018-01-09 | 朗致集团江西医药有限公司 | A kind of pharmaceutical composition for treating cardiovascular and cerebrovascular disease and its application and the injection formed by its preparation |
| CN107753497A (en) * | 2017-10-18 | 2018-03-06 | 朗致集团万荣药业有限公司 | A kind of pharmaceutical composition containing narcissin and preparation method thereof and purposes |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101492350A (en) * | 2009-03-05 | 2009-07-29 | 上海交通大学 | Method for producing D-pinit from plant locust |
| CN101612142A (en) * | 2008-06-25 | 2009-12-30 | 广州威尔曼新药开发中心有限公司 | Inositol derivative or the purposes of its salt in pharmacy |
| CN101808628A (en) * | 2007-09-05 | 2010-08-18 | 索建特股份有限公司 | Composition for prevention or treatment of bone metabolism disorder comprising d-pinitol as an active ingredient |
-
2013
- 2013-02-21 CN CN201310055954.8A patent/CN103202824B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101808628A (en) * | 2007-09-05 | 2010-08-18 | 索建特股份有限公司 | Composition for prevention or treatment of bone metabolism disorder comprising d-pinitol as an active ingredient |
| CN101612142A (en) * | 2008-06-25 | 2009-12-30 | 广州威尔曼新药开发中心有限公司 | Inositol derivative or the purposes of its salt in pharmacy |
| CN101492350A (en) * | 2009-03-05 | 2009-07-29 | 上海交通大学 | Method for producing D-pinit from plant locust |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103202824A (en) | 2013-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Eliseeva et al. | Vitamin C (ascorbic acid)–description, benefits and where it is found | |
| US8197854B2 (en) | Nutritional supplement for use under physiologically stressful conditions | |
| US10485836B2 (en) | Anti-fatigue composition used for increasing endurance performance, and use of the same | |
| EP1763359B1 (en) | Use of pregnane glycosides in the treatment/management of obesity | |
| US10149882B2 (en) | Weight management systems and related methods | |
| CN103202824B (en) | Application of pinitol to pharmacy and health care product | |
| US20200113982A1 (en) | Composition and Uses Thereof | |
| CN110754656A (en) | Special clinical nutrition formula for lymphoma function and preparation method thereof | |
| WO1999047006A1 (en) | Foods, medical treatments and method relating to effects of promoting the growth of lactobacillus bifidus, preventing allergy and lowering human cholesterol level | |
| CN101433329B (en) | Nutritive composition with health-care function | |
| KR101266889B1 (en) | Functional food compositions having the recovery effect of blood composition and function | |
| CN104770644A (en) | Diabetes health care product based on affinal drugs and diet | |
| CN103798596B (en) | Total nutrient formula food suitable for patients with cardiovascular and cerebrovascular diseases | |
| US20180228860A1 (en) | Method for regulating expressions of tph1 gene, ddc gene, and/or aanat gene by using banana peel extract | |
| KR100441308B1 (en) | A diet ginseng drink and the preparing method thereof | |
| US20200306231A1 (en) | Oral hypoglycemic agents as food additives and supplements | |
| KR102701265B1 (en) | Ultra-low calrorie food composition comprising a protein of high bioabsorption rate, and a method for providing dietary information using the same | |
| US6599522B2 (en) | Triglyceride reducing agent | |
| US11185565B2 (en) | Compositions including milk thistle and methods of use | |
| CN108236714B (en) | Composition for relieving physical fatigue and assisting in reducing blood fat and soft capsule thereof | |
| Desai et al. | Role of antioxidant therapy in management of type-2 diabetes mellitus | |
| KR20220021874A (en) | Ultra-low calrorie food composition comprising a protein of high bioabsorption rate, and a method for providing dietary information using the same | |
| KR101397044B1 (en) | Novel Use of Asterubine | |
| CN114916669A (en) | Antioxidative health food containing salmon roe and preparation method and application thereof | |
| CN112450436A (en) | Composition with function of improving cardiovascular function and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150520 Termination date: 20160221 |